The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 935
The physiological interactome of TCR-like antibody therapeutics in human tissues
Marrer‐Berger, E., Nicastri, A., Augustin, A., Kramar, V., Liao, H., Hanisch, L. J., Carpy, A., Weinzierl, T., Durr, E., Schaub, N. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47062-5 · Cited by 20
New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma
Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00443-8 · Cited by 20
Self-citationRecent advances in understanding the role of HES6 in cancers
Krossa, I., Strub, T., Martel, A., Nahon‐Estève, S., Lassalle, S., Hofman, P. M., Baillif, S., Ballotti, R., & Bertolotto, C. (2022) · Theranostics · doi:10.7150/thno.72966 · Cited by 22
Advancements in therapeutic peptides: Shaping the future of cancer treatment
Chen, X., Zhao, Z., Laster, K. V., Liu, K., & Dong, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189197 · Cited by 19
Güç, E., Treveil, A., Leach, E., Broomfield, A., Camera, A., Clubley, J., Nieto, P., Kazachenka, A., Khanolkar, R. C., del Carpio, L. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57470-w · Cited by 19
Self-citationBozym, D. J., Zheng, D. X., Revach, O., Aref, A. R., & Jenkins, R. W. (2025) · Lab on a Chip · doi:10.1039/d5lc00062a · Cited by 20
HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies
Lau, J. S. Y., Lewin, S. R., & Telwatte, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1650852 · Cited by 19
Regulatory T Cell Therapeutics for Neuroinflammatory Disorders
Harkins, A. L., Kopec, A. L., & Keeler, A. M. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2022045080 · Cited by 19
Corrales, L. P., Hipp, S., Martin, K., Sabarth, N., Tirapu, I., Fuchs, K., Thaler, B., Walterskirchen, C., Bauer, K. H., Fabits, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1008764 · Cited by 19
FDA Approvals of Biologics in 2022
Martins, A. C., Alberício, F., & de la Torre, B. G. (2023) · Biomedicines · doi:10.3390/biomedicines11051434 · Cited by 20
Curing Stage IV Melanoma: Where Have We Been and Where Are We?
Chan, P. Y., & Corrie, P. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438654 · Cited by 19
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 19
Sacco, J. J., Kirk, P. B., Leach, E., Shoushtari, A. N., Carvajal, R. D., Britton-Rivet, C., Khakoo, S., Collins, L. C., de la Cruz‐Merino, L., Eroglu, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102076 · Cited by 18
Self-citationChan, P. Y., Alexander, D., Mehta, I., Matsuyama, L. S. A. S., Harle, V. J., Olvera-León, R., Park, J. S., Arriaga-González, F. G., van der Weyden, L., Cheema, S., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02222-1 · Cited by 19
Discovery of predictive biomarkers for cancer therapy through computational approaches
Wang, X., Nguyen, J., Nader, K. M., Miihkinen, M., Wall, P., Singhal, A., Bedard, P. L., Ideker, T., Aittokallio, T. A., & Haibe‐Kains, B. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01109-8 · Cited by 24
Retinoblastoma and uveal melanoma in Jordan: incidence, demographics, and survival (2011-2020)
Yousef, Y. A., Mohammad, M. T., AlNawaiseh, I., Mahafza, H., Halalsheh, H., Mehyar, M., AlJabari, R., Alrawashdeh, K., Jaradat, I., Sultan, I. Y., et al. (2022) · Ophthalmic Genetics · doi:10.1080/13816810.2022.2090008 · Cited by 18
TCR mimic compounds for pHLA targeting with high potency modalities in oncology
Gerber, H., & Presta, L. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1027548 · Cited by 18
Francis, J. H., Barker, C. A., Brannon, A. R., Canestraro, J., Robbins, M. A., Swartzwelder, C. E., Levine, S., Law, C. W., Berger, M. F., Shoushtari, A. N., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.13.17 · Cited by 18
Self-citationArang, N., Lubrano, S., Rigiracciolo, D. C., Nachmanson, D., Lippman, S. M., Mali, P., Harismendy, O., & Gutkind, J. S. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102866 · Cited by 20
Tang, H., Wang, B., Tan, H.-X., Sarwar, M., Baraka, B., Shafiq, T., & Rao, A. (2023) · Cells · doi:10.3390/cells12121586 · Cited by 15
Detection of metastases using circulating tumour DNA in uveal melanoma
Beasley, A. B., de Bruyn, D. P., Calapre, L., Al‐Ogaili, Z., Isaacs, T., Bentel, J. M., Reid, A. L., Dwarkasing, R. S., Pereira, M. R., Khattak, M. A., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05271-3 · Cited by 18
FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma
Abbas, Z., Wally, H. T., & Qureshi, F. A. (2023) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.9359 · Cited by 18
Huibers, A. E., DePalo, D. K., Perez, M. C., Zager, J. S., & Bagge, R. O. (2023) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10234-6 · Cited by 18
Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments
Lee, S., & Kim, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417634 · Cited by 18
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia
Leung, W. K., Chavez, A. G. T., French-Kim, M., Shafer, P. W., Mamonkin, M., Hill, L. C., Kuvalekar, M., Velazquez, Y., Watanabe, A., Watanabe, N., et al. (2024) · Blood · doi:10.1182/blood.2023021979 · Cited by 18
Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma
de Bruyn, D. P., van Poppelen, N. M., Brands, T., van den Boom, S. C., Eikenboom, E. L., Wagner, A., van Veghel–Plandsoen, M. M., Geeven, G., Beverloo, B. H. B., van Rij, C. M., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.2.11 · Cited by 18
Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations
Liu, X., Run‐hua, Z., Pan, J., Li, Z., Yu, L., & Li, Y. (2024) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13161 · Cited by 20
Spreafico, A., Muñoz‐Couselo, E., Irmisch, A., Bessa, J., Au‐Yeung, G., Bechter, O. E., Svane, I. M., Sanmamed, M. F., Gambardella, V., McKean, M. A., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1346502 · Cited by 18
Self-citationDian, Y., Liu, Y., Zeng, F., Sun, Y., & Deng, G. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2374647 · Cited by 18
Jackson, M., Kalirai, H., Hussain, R. N., Heimann, H., Zheng, Y., & Coupland, S. E. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100647 · Cited by 18
Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review
Ma, P., Jiang, Y., Zhao, G., Wang, W., Xing, S., Tang, Q., Miao, H., Fang, H., Chao, S., Yuan, F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114224 · Cited by 17
Tebentafusp in first-line melanoma trials: An outperforming outlier
Olivier, T., & Prasad, V. K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101408 · Cited by 17
Liu, D., Qi, X., Wei, X., Zhao, L., Wang, X., Li, S., Wang, Z., Shi, L., Xu, J., Mei, H., et al. (2022) · Theranostics · doi:10.7150/thno.75037 · Cited by 17
Evolving Management of Stage IV Melanoma
Switzer, B., Piperno-Neumann, S., Lyon, J., Buchbinder, E. I., & Puzanov, I. J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397478 · Cited by 18
Self-citationRECISTv1.1 progression in oncology: Shades of gray
Topp, B. G., Snyder, A., & Wolchok, J. D. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.012 · Cited by 17
Jarczak, J., Karska‐Basta, I., & Romanowska-Dixon, B. (2023) · Medicina · doi:10.3390/medicina59061131 · Cited by 17
Pandey, K., Wang, S. S., Mifsud, N. A., Faridi, P., Davenport, A. J., Webb, A. I., Sandow, J. J., Ayala, R., Monje, M., Cross, R. S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1192448 · Cited by 17
PAK1 and Therapy Resistance in Melanoma
Kichina, J. V., Maslov, A. A., & Kandel, E. (2023) · Cells · doi:10.3390/cells12192373 · Cited by 18
Individualised neoantigen cancer vaccine therapy
Terai, M., & Sato, T. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02463-7 · Cited by 17
Bagge, R. O., Nelson, A., Shafazand, A., Cahlin, C., Carneiro, A., Helgadottir, H. T., Levin, M., Rizell, M., Ullenhag, G. J., Wirén, S. M., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103623 · Cited by 18
Stålhammar, G., Hagström, A., Conradi, M. E., & Williams, P. A. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.09.004 · Cited by 17
TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
Strobel, S. B., Machiraju, D., & Hassel, J. C. (2022) · Cancers · doi:10.3390/cancers14051215 · Cited by 18
Self-citationSalaün, H., de Koning, L., Saint‐Ghislain, M., Servois, V., Ramtohul, T., Garcia, A., Matet, A., Cassoux, N., Mariani, P., Piperno-Neumann, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2116845 · Cited by 17
Self-citationCD4 T cells and toxicity from immune checkpoint blockade
Earland, N. J., Zhang, W., Usmani, A., Nene, A., Bacchiocchi, A., Chen, D. Y., Sznol, M., Halaban, R., Chaudhuri, A. A., & Newman, A. M. (2023) · Immunological Reviews · doi:10.1111/imr.13248 · Cited by 19
Gerber, W. K., Xie, Y., & Patel, S. A. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00753 · Cited by 17
Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
Wong, D., Luo, P., Znassi, N., Arteaga, D. P., Gray, D., Danesh, A., Han, M., Stutheit-Zhao, E. Y., Pedersen, S., Prokopec, S. D., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0456 · Cited by 16
Self-citationBaradaran, M. (2023) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp-134049 · Cited by 16
Mariani, P., Bidard, F., Rampanou, A., Houy, A., Servois, V., Ramtohul, T., Pierron, G., Chevrier, M., Renouf, B., Lantz, O. J., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005822 · Cited by 16
Self-citationA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02465-x · Cited by 16
Mariani, P., Torossian, N., Laere, S. V., Vermeulen, P., de Koning, L., Roman‐Roman, S., Lantz, O. J., Rodrigues, M. J., Stern, M., Gardrat, S., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02331-w · Cited by 16
Self-citationSurveillance for Metastasis in High-Risk Uveal Melanoma Patients: Standard versus Enhanced Protocols
Yeşiltaş, Y. S., Zabor, E. C., Wrenn, J. M., Oakey, Z. B., & Singh, A. D. (2023) · Cancers · doi:10.3390/cancers15205025 · Cited by 16
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
Park, J., Hamad, S. A., Stewart, A., Carlino, M. S., Lim, S. Y., & Rizos, H. (2024) · Oncogenesis · doi:10.1038/s41389-024-00511-8 · Cited by 16
The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review
Wang, J., Li, Z., & Yin, H. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00913-2 · Cited by 16
Song, M., Zhu, L., Zhang, L., Ge, X., Cao, J., Teng, Y., & Tian, R. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01117 · Cited by 16
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
Koch, E. A. T., Heppt, M. V., & Berking, C. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00872-1 · Cited by 16
Advances in Vaccines for Melanoma
Cui, C., Ott, P. A., & Wu, C. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.009 · Cited by 16
Zhang, X., Qiu, J., Huang, F., Han, P., Shan, K. Y., & Zhang, C. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109214 · Cited by 16
Precision Oncology: 2022 in Review
Rosen, E. Y., Drilon, A. E. D. C., & Chakravarty, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1154 · Cited by 16
Expert recommendations on diagnostic-therapeutic management of melanoma patients
Rutkowski, P. L., Wysocki, P. J., Kozak, K., Nasierowska-Guttmejer, A. M., Jeziorski, A., Wysocki, W. M., Kalinka‐Warzocha, E., Świtaj, T., Kamińska‐Winciorek, G., Czarnecka, A. M., et al. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0042 · Cited by 21
Self-citationVerma, V., & Sharma, G. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01520-y · Cited by 15
Staeger, R., Tastanova, A., Ghosh, A., Winkelbeiner, N., Shukla, P., Kolm, I., Turko, P., Benlahrech, A., Harper, J. V., Broomfield, A., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181464 · Cited by 16
Self-citationAedo-Lopez, V., Gerard, C. L., Boughdad, S., Moura, B. G., Berthod, G., Digklia, A., Homicskó, K., Schaefer, N. G., Durán, R., Cuendet, M. A., et al. (2022) · Cancers · doi:10.3390/cancers14051162 · Cited by 15
Emerging Nano‐Immunotherapeutic Approaches to Glioma
Jin, N., Yang, W., Xie, Y., Yu, M., Chen, Y., & Zhang, J. (2023) · Small Structures · doi:10.1002/sstr.202300016 · Cited by 15
Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting
Wallace, Z., Heunis, T. D. J., Paterson, R. L., Suckling, R. J., Grant, T., Dembek, M., Donoso, J., Brener, J., Long, J., Bunjobpol, W., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.010 · Cited by 15
Tonelotto, V., Costa-García, M., O’Reilly, E., Smith, K. F., Slater, K., Dillon, E., Pendino, M., Higgins, C., Sist, P., Bosch, R., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01773-8 · Cited by 16
Self-citationReassessing human MHC-I genetic diversity in T cell studies
Slieker, R. C., Warmerdam, D. O., Vermeer, M. H., van Doorn, R., Heemskerk, M. H. M., & Scheeren, F. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-58777-2 · Cited by 15
Targeted therapy in ophthalmic oncology: The current status
Sen, M., Demirci, H., & Honavar, S. G. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2024.100062 · Cited by 15
Paterson, R. L., Manna, M. P. L., Souza, V. A. D., Walker, A., Gibbs‐Howe, D., Kulkarni, R., Fergusson, J. R., Mulakkal, N. C., Monteiro, M., Bunjobpol, W., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318003121 · Cited by 15
Mahumud, R. A., Shahjalal, M., Dahal, P. K., Mosharaf, M. P., Hoque, M. E., & Wawryk, O. (2024) · BMC Cancer · doi:10.1186/s12885-024-12560-8 · Cited by 15
Wang, Y., Bergman, D. R., Trujillo, E., Fernald, A. A., Li, L., Pearson, A. T., Sweis, R. F., & Jackson, T. L. (2024) · Cancers · doi:10.3390/cancers16172942 · Cited by 15
How we treat patients with metastatic uveal melanoma
Saldanha, E. F., Ribeiro, M. F., Hirsch, I., Spreafico, A., Saibil, S. D., & Butler, M. O. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104496 · Cited by 15
Self-citationLiu, A., Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2031970 · Cited by 15
Self-citationSpecific human endogenous retroviruses predict metastatic potential in uveal melanoma
Bendall, M. L., Francis, J. H., Shoushtari, A. N., & Nixon, D. F. (2022) · JCI Insight · doi:10.1172/jci.insight.147172 · Cited by 15
Self-citationTong, T. M. L., Samim, M., Kapiteijn, E., Meijer, T. S., Speetjens, F. M., Brüning, R., Schroeder, T. H., El-Sanosy, S., Maschke, H., Wacker, F. K., et al. (2022) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-022-03225-9 · Cited by 15
Atkins, M. B., Abu‐Sbeih, H., Ascierto, P. A., Bishop, M., Chen, D. S., Dhodapkar, M. V., Emens, L. A., Ernstoff, M. S., Ferris, R. L., Greten, T. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005413 · Cited by 15
Wattana, M. K., Rowland, J., Qdaisat, A. Z., Levavi, H., Anagnostou, T., Sanchez, L. J., Friedlander, P. A., Rohs, N. C., Lipe, D. N., & Richter, J. R. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102889 · Cited by 14
Raybould, M. I. J., Nissley, D. A., Kumar, S., & Deane, C. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1080596 · Cited by 14
The expanding success of T cell-engaging bispecific antibodies
Bargou, R. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00586-z · Cited by 14
Immunogenetic Diversity and Cancer Immunotherapy Disparities
de Miranda, N. F. C. C., & Scheeren, F. A. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1536 · Cited by 14
Martín-Antonio, B., Blanco, B., González‐Murillo, Á., Hidalgo, L., Minguillón, J., & Pérez-Chacón, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386856 · Cited by 14
Reschke, R., Enk, A. H., & Hassel, J. C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081046 · Cited by 14
Self-citationImmunotherapy in the Fight Against Bone Metastases: A Review of Recent Developments and Challenges
Peng, Z., Huang, W. P., Xiao, Z., Wang, J., Zhu, Y., Zhang, F., Lan, D., & He, F. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01256-7 · Cited by 16
Dimitriou, F., Orloff, M. M., Hein, E. C. K., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115161 · Cited by 14
Self-citationTebentafusp for uveal melanoma
Killock, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00572-3 · Cited by 14
Sex‐based differences in early and late uveal melanoma‐related mortality
Stålhammar, G. (2022) · Cancer Medicine · doi:10.1002/cam4.5458 · Cited by 14
Cancer Immunotherapy Beyond Checkpoint Blockade
Welty, N. E., & Gill, S. I. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.006 · Cited by 16
Tarin, M., Némati, F., Decaudin, D., Canbezdi, C., Marande, B., Silva, L. E., Derrien, H., Jochemsen, A. G., Gardrat, S., Piperno-Neumann, S., et al. (2023) · Cancers · doi:10.3390/cancers15082280 · Cited by 14
Self-citationFerroptosis induced by DCPS depletion diminishes hepatic metastasis in uveal melanoma
Jin, B., Yang, L., Ye, Q., & Pan, J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115625 · Cited by 14
Ensuring equity in the era of HLA-restricted cancer therapeutics
Smithy, J. W., Blouin, A. G., Diamond, L. C., & Postow, M. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005600 · Cited by 14
The tumor microenvironment: adding pieces to the puzzle
Aguilar‐Cázares, D., Perez-Medina, M., Benito-Lopez, J. J., Galicia-Velasco, M., Meneses-Flores, M., Camarena, Á., & López-González, J. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1731338 · Cited by 13
Rurik, J. G., & Epstein, J. A. (2022) · DNA and Cell Biology · doi:10.1089/dna.2022.0171 · Cited by 13
Guo, X., Yu, X., Zhang, Y., Luo, H., Huang, R. S., Zeng, Y., Duan, C., & Chen, C. (2023) · Ophthalmic Research · doi:10.1159/000529818 · Cited by 13
Marcinek, A., Brauchle, B., Rohrbacher, L., Hänel, G., Philipp, N., Märkl, F., Strzalkowski, T., Lacher, S. M., Udiljak, D., Spiekermann, K., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03439-x · Cited by 13
Shen, M., Chen, S., Han, X., Hao, Y., Wang, J., Luo, L., Chen, T., Wang, B., Zou, L., Zhang, T., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03729-y · Cited by 13
Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review
Xu, J., Mu, S., Wang, Y., Yu, S., & Wang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1400193 · Cited by 13
GP100 expression is variable in intensity in melanoma
Mann, J. E., Hasson, N., Su, D. G., Adeniran, A., Smalley, K. S. M., Djureinovic, D., Jilaveanu, L. B., Schoenfeld, D. A., & Kluger, H. M. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03776-5 · Cited by 13
Tailoring surveillance imaging in uveal melanoma based on individual metastatic risk
Hagström, A., Witzenhausen, H., & Stålhammar, G. (2024) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2024.07.014 · Cited by 13
Lopez, J. S., Milhem, M. M., Butler, M. O., Thistlethwaite, F. C., Tine, B. A. V., D’Angelo, S. P., Johnson, M. L., Sato, T., Arkenau, H., Edukulla, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101994 · Cited by 13
Self-citationA Rare Case of Glioblastoma With Extensive Liver Metastases
Ghous, G. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3511.0733 · Cited by 13
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
